BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987
520 results:

  • 1. [Well-differentiated/dedifferentiated liposarcoma associated with myxoid-like morphology: a clinicopathological and molecular genetic characteristics analysis of 34 cases].
    Xue S; Liu QY; Gou XN; Zhao YW; Cheng Q; Kong LF
    Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):168-173. PubMed ID: 38281785
    [No Abstract]    [Full Text] [Related]  

  • 2. mdm2 provides TOP2 poison resistance by promoting proteolysis of TOP2βcc in a p53-independent manner.
    Shu J; Jiang J; Wang X; Yang X; Zhao G; Cai T
    Cell Death Dis; 2024 Jan; 15(1):83. PubMed ID: 38263255
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2.
    Kim D; Min D; Kim J; Kim MJ; Seo Y; Jung BH; Kwon SH; Ro H; Lee S; Sa JK; Lee JY
    J Exp Clin Cancer Res; 2023 Dec; 42(1):338. PubMed ID: 38093368
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Genomic Landscape of Pulmonary Sarcomatoid Carcinoma.
    Kwon HJ; Lee S; Han YB; Lee J; Kwon S; Kim H; Chung JH
    Cancer Res Treat; 2024 Apr; 56(2):442-454. PubMed ID: 37973906
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Pathway-driven analysis of synthetic lethal interactions in cancer using perturbation screens.
    Karimpour M; Totonchi M; Behmanesh M; Montazeri H
    Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37863651
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Tetrahydrobiopterin from cyanide-degrading bacterium Bacillus pumilus strain SVD06 induces apoptosis in human lung adenocarcinoma cell (A549).
    Mahendran R; Selvaraj SP; Dhanapal AR; Sarasa SB; Mathias BM; Thankappan B; Femil Selta DR; Naveen P; Poorani R; Sundhar N; Pillai MM; Selvakumar R; Huang CY; Eswaran R; Angayarkanni J
    Biotechnol Appl Biochem; 2023 Dec; 70(6):2052-2068. PubMed ID: 37731306
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Designed novel nuclear localizing anticancer peptide targets p53 negative regulator mdm2 protein.
    Mukherjee N; Bhunia D; Garai PK; Mondal P; Barman S; Ghosh S
    J Pept Sci; 2024 Jan; 30(1):e3535. PubMed ID: 37580909
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Odontogenic Carcinosarcoma: Clinicopathologic and Molecular Features of Three Cases, a Literature Review and Nomenclature Proposal.
    Cole G; Chi A; Cook DR; Kubik M; Bilodeau EA; Seethala RR
    Head Neck Pathol; 2023 Sep; 17(3):751-767. PubMed ID: 37486533
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. mdm2-mediated Inhibitory Effect of Arsenic Trioxide on Small Cell lung cancer Cell Line by Degrading Mutant p53.
    Wang YS; Yin JZ; Shi XQ; Zhao XW; Li B; Yang MH
    Anticancer Agents Med Chem; 2023; 23(16):1829-1837. PubMed ID: 37259217
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Design, Synthesis and Antitumor Activity of 1
    Wang C; Zhu M; Long X; Wang Q; Wang Z; Ouyang G
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240028
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Combination Therapy With mdm2 and MEK Inhibitors Is Effective in Patient-Derived Models of lung Adenocarcinoma With Concurrent Oncogenic Drivers and mdm2 Amplification.
    Elkrief A; Odintsov I; Markov V; Caeser R; Sobczuk P; Tischfield SE; Bhanot U; Vanderbilt CM; Cheng EH; Drilon A; Riely GJ; Lockwood WW; de Stanchina E; Tirunagaru VG; Doebele RC; Quintanal-Villalonga Á; Rudin CM; Somwar R; Ladanyi M
    J Thorac Oncol; 2023 Sep; 18(9):1165-1183. PubMed ID: 37182602
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Prevalence, causes and impact of TP53-loss phenocopying events in human tumors.
    Fito-Lopez B; Salvadores M; Alvarez MM; Supek F
    BMC Biol; 2023 Apr; 21(1):92. PubMed ID: 37095494
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. mRNA markers associated with malignant pleural effusion.
    Hsu SC; Chang SY; Hwang YT; Terng HJ; Tsai CL; Shen CH; Huang SK; Chian CF
    Sci Rep; 2023 Apr; 13(1):6677. PubMed ID: 37095178
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Targeting neddylation as a novel approach to lung cancer treatment (Review).
    Tian Z; Li J; Ma R; Li T; Sun Z; Huang S
    Int J Oncol; 2023 May; 62(5):. PubMed ID: 37083098
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Epigenetic silencing of ZCCHC10 by the lncRNA SNHG1 promotes progression and venetoclax resistance of acute myeloid leukemia.
    Zhou H; Zhang Q; Huang W; He C; Zhou C; Zhou J; Ning Y
    Int J Oncol; 2023 May; 62(5):. PubMed ID: 37052262
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Uterine MEIS1::NCOA2 Fusion Sarcoma With lung Metastasis: A Case Report and Review of the Literature.
    Xing D; Meyer CF; Gross JM; Argani P; Hung CF; Wu TC; Vang R; Armstrong DK; Gaillard SL
    Int J Gynecol Pathol; 2024 Jan; 43(1):47-55. PubMed ID: 37043646
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The RNA binding protein RALY suppresses p53 activity and promotes lung tumorigenesis.
    Hu H; Zhao K; Fang D; Wang Z; Yu N; Yao B; Liu K; Wang F; Mei Y
    Cell Rep; 2023 Apr; 42(4):112288. PubMed ID: 36952348
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Mutational Damages in Malignant lung Tumors.
    Yermekova S; Orazgaliyeva M; Goncharova T; Rakhimbekova F; Dushimova Z; Vasilieva T
    Asian Pac J Cancer Prev; 2023 Feb; 24(2):709-716. PubMed ID: 36853323
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.
    Tucker ER; Jiménez I; Chen L; Bellini A; Gorrini C; Calton E; Gao Q; Che H; Poon E; Jamin Y; Martins Da Costa B; Barker K; Shrestha S; Hutchinson JC; Dhariwal S; Goodman A; Del Nery E; Gestraud P; Bhalshankar J; Iddir Y; Saberi-Ansari E; Saint-Charles A; Geoerger B; Marques Da Costa ME; Pierre-Eugène C; Janoueix-Lerosey I; Decaudin D; Nemati F; Carcaboso AM; Surdez D; Delattre O; George SL; Chesler L; Tweddle DA; Schleiermacher G
    Clin Cancer Res; 2023 Apr; 29(7):1317-1331. PubMed ID: 36602782
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of novel protopanoxadiol derivatives based PROTACs technology for the treatment of lung cancer.
    Wang P; Zhu H; Liu J; Xie S; Xu S; Chen Y; Xu J; Zhao Y; Zhu Z; Xu J
    Bioorg Chem; 2023 Feb; 131():106327. PubMed ID: 36549254
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 26.